Stock A032300 KOREA PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News KOREA PHARMA Co., Ltd.

Equities

A032300

KR7032300006

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
19,240 KRW -0.31% Intraday chart for KOREA PHARMA Co., Ltd. +2.72% -18.65%
2023 Astrogen Co.,Ltd. announced that it has received KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd. CI
2023 KOREA PHARMA Co., Ltd. announced that it has received KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Astrogen Co.,Ltd. announced that it has received KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd.
CI
KOREA PHARMA Co., Ltd. announced that it has received KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd.
CI
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 23 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., EBEST Investment & Securities Co., Ltd. and others
CI
Astrogen Co.,Ltd. announced that it expects to receive KRW 2.999998662 billion in funding from KOREA PHARMA Co., Ltd.
CI
KOREA PHARMA Co., Ltd.(KOSDAQ:A032300) dropped from S&P Global BMI Index
CI
KOREA PHARMA Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Shield Therapeutics plc - Full Year Trading Update
AQ
Shield announces regulatory pathway and timelines for Accrufer approval in the Republic of Korea
AQ
KOREA PHARMA Co., Ltd. announced that it has received KRW 50 billion in funding
CI
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 50 billion in funding
CI
Shield Therapeutics : Licence agreement secured in Republic of Korea for Accrufer
AQ
KOREA PHARMA Co., Ltd.(KOSDAQ:A032300) added to S&P Global BMI Index
CI
KOREA PHARMA Co., Ltd. has completed an IPO in the amount of KRW 29.187 billion.
CI
KOREA PHARMA Co., Ltd. has filed an IPO.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A032300 Stock
  4. News KOREA PHARMA Co., Ltd.